Capillary electrophoresis in the analysis of therapeutic peptides-A review.
biopharmaceuticals
capillary electrophoresis
mass spectrometry
quality control and bioanalysis
therapeutic peptides
Journal
Electrophoresis
ISSN: 1522-2683
Titre abrégé: Electrophoresis
Pays: Germany
ID NLM: 8204476
Informations de publication
Date de publication:
14 Sep 2023
14 Sep 2023
Historique:
revised:
10
08
2023
received:
29
06
2023
accepted:
14
08
2023
medline:
14
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
aheadofprint
Résumé
Therapeutic peptides are a growing class of innovative drugs with high efficiency and a low risk of adverse effects. These biomolecules fall within the molecular mass range between that of small molecules and proteins. However, their inherent instability and potential for degradation underscore the importance of reliable and effective analytical methods for pharmaceutical quality control, therapeutic drug monitoring, and compliance testing. Liquid chromatography-mass spectrometry (LC-MS) has long time been the "gold standard" conventional method for peptide analysis, but capillary electrophoresis (CE) is increasingly being recognized as a complementary and, in some cases, superior, highly efficient, green, and cost-effective alternative technique. CE can separate peptides composed of different amino acids owing to differences in their net charge and size, determining their migration behavior in an electric field. This review provides a comprehensive overview of therapeutic peptides that have been used in the clinical environment for the last 25 years. It describes the properties, classification, current trends in development, and clinical use of therapeutic peptides. From the analytical point of view, it discusses the challenges associated with the analysis of therapeutic peptides in pharmaceutical and biological matrices, as well as the evaluation of CE as a whole and the comparison with LC methods. The article also highlights the use of microchip electrophoresis, nonaqueous CE, and nonconventional hydrodynamically closed CE systems and their applications. Overall, the article emphasizes the importance of developing new CE-based analytical methods to ensure the high quality, safety, and efficacy of therapeutic peptides in clinical practice.
Identifiants
pubmed: 37705480
doi: 10.1002/elps.202300141
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : UK/53/2023
Organisme : VEGA 1/0514/22
Organisme : VEGA 2/0078/22
Organisme : VEGA 2/0129/21
Organisme : APVV-21-0321
Informations de copyright
© 2023 Wiley-VCH GmbH.
Références
Cicero AFG, Fogacci F, Colletti A. Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review. Br J Pharmacol. 2017;174:1378-1394.
Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26:2700-2707.
Albericio F, Kruger HG. Therapeutic peptides. Future Med Chem. 2012;4:1527-1531.
Piestansky J, Barath P, Majerova P, Galba J, Mikus P, Kovacech B, et al. A simple and rapid LC-MS/MS and CE-MS/MS analytical strategy for the determination of therapeutic peptides in modern immunotherapeutics and biopharmaceutics. J Pharm Biomed Anal. 2020;189:113449.
Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12:141-146.
Elkinton JR, Hunt AD Jr, Godfrey L, McCrory WW, Rogerson AG, Stokes J Jr. Effects of pituitary adrenocorticotropic hormone (ACTH) therapy. J Am Med Assoc. 1949;141:1273-1279.
Taylor M, Moore S, Mayes J, Parkin E, Beeg M, Canovi M, et al. Development of a proteolytically stable retro-inverso peptide inhibitor of β-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry. 2010;49:3261-3272.
Henninot A, Collins JC, Nuss JM. The current state of peptide drug discovery: back to the future? J Med Chem. 2018;61:1382-1414.
Werner HM, Cabalteja CC, Horne WS. Peptide backbone composition and protease susceptibility: impact of modification type, position, and tandem substitution. ChemBioChem. 2016;17:712-718.
Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015;17:134-143.
Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20:122-128.
Diamond G, Beckloff N, Weinberg A, Kisich KO. The roles of antimicrobial peptides in innate host defense. Curr Pharm Des. 2009;15:2377-2392.
Tan TM-M, Khoo B. Tirzepatide and the new era of twincretins for diabetes. Lancet. 2021;398:95-97.
EMA. Mounjaro. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro. Accessed 19 Apr 2023.
FDA Approves Novel. Dual-targeted treatment for type 2 diabetes. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes. Accessed 19 Apr 2023.
Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003;2:587-593.
Thayer AM. Making peptides at large scale. Chem Eng News Arch. 2011;89:21-25.
Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Peptide Sci. 2016;22:4-27.
Lian Z, Wang N, Tian Y, Huang L. Characterization of synthetic peptide therapeutics using liquid chromatography-mass spectrometry: challenges, solutions, pitfalls, and future perspectives. J Am Soc Mass Spectrom. 2021;32:1852-1860.
Sharma N, Kukreja D, Giri T, Kumar S, Shah RP. Synthetic pharmaceutical peptides characterization by chromatography principles and method development. J Sep Sci. 2022;45:2200-2216.
Zhu Q, Scriba GKE. Analysis of small molecule drugs, excipients and counter ions in pharmaceuticals by capillary electromigration methods-recent developments. J Pharm Biomed Anal. 2018;147:425-438.
Krait S, Konjaria M, Scriba GKE. Advances of capillary electrophoresis enantioseparations in pharmaceutical analysis (2017-2020). Electrophoresis. 2021;42:1709-1725.
Lucana MC, Arruga Y, Petrachi E, Roig A, Lucchi R, Oller-Salvia B. Protease-resistant peptides for targeting and intracellular delivery of therapeutics. Pharmaceutics. 2021;13:2065.
Ahmad A, Yadav SP, Asthana N, Mitra K, Srivastava SP, Ghosh JK. Utilization of an amphipathic leucine zipper sequence to design antibacterial peptides with simultaneous modulation of toxic activity against human red blood cells. J Biol Chem. 2006;281:22029-22038.
Shima F, Akagi T, Akashi M. The role of hydrophobicity in the disruption of erythrocyte membrane by nanoparticles composed of hydrophobically modified poly(γ-glutamic acid). J Biomater Sci Polym Ed. 2014;25:203-210.
Baig MH, Ahmad K, Saeed M, Alharbi AM, Barreto GE, Ashraf GM, et al. Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases. Biomed Pharmacother. 2018;103:574-581.
Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines (Basel). 2014;2:515-536.
Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci. 2017;24:21.
Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem. 2012;19:3794-3804.
Li Y, Clark KA, Tan Z. Methods for engineering therapeutic peptides. Chin Chem Lett. 2018;29:1074-1078.
Timmermans PB. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res. 1999;22:147-153.
Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7:1-27.
Fricker G, Bruns C, Munzer J, Briner U, Albert R, Kissel T, et al. Intestinal absorption of the octapeptide SMS. 201-995 visualized by fluorescence derivatization. Gastroenterology. 1991;100:1544-1552.
Smith GP, Petrenko VA. Phage display. Chem Rev. 1997;97:391-410.
Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672-1681.
Sachdeva S. Peptides as ‘drugs’: the journey so far. Int J Pept Res Ther. 2017;23:49-60.
Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4:1443-1467.
European Commission. Public health-Union Register of medicinal products. European Commission. https://ec.europa.eu/health/documents/community-register/html/index_en.htm. Accessed 19 Apr 2023.
Makuch RW, Shi R. Comparison of drug approvals in Europe versus the United States. Ther Innov Regul Sci. 2014;48:362-366.
Al Musaimi O, Al Shaer D, Albericio F, de la Torre B. 2020 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals. 2021;14:145.
Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2021 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals. 2022;15:222.
Al Musaimi O, Al Shaer D, Albericio F, de la Torre BG. 2022 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals. 2023;16:336.
Anand U, Bandyopadhyay A, Jha NK, Pérez de la Lastra JM, Dey A. Translational aspect in peptide drug discovery and development: an emerging therapeutic candidate. Biofactors. 2023;49:251-269.
Xie M, Liu D, Yang Y. Anti-cancer peptides: classification, mechanism of action, reconstruction and modification. Open Biol. 2022;10:200004.
Xiao Y-F, Jie M-M, Li B-S, Hu C-J, Xie R, Tang B, et al. Peptide-based treatment: a promising cancer therapy. J Immunol Res. 2015;2015:e761820.
Li CM, Haratipour P, Lingeman RG, Perry JJP, Gu L, Hickey RJ, et al. Novel peptide therapeutic approaches for cancer treatment. Cells. 2021;10:2908.
Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids. 2012;2012:967347.
Samec T, Boulos J, Gilmore S, Hazelton A, Alexander-Bryant A. Peptide-based delivery of therapeutics in cancer treatment. Mater Today Bio. 2022;14:100248.
Gao Y, Yuan X, Zhu Z, Wang D, Liu Q, Gu W. Research and prospect of peptides for use in obesity treatment (Review). Exp Ther Med. 2020;20:1.
Castillo-Díaz LA, Ruiz-Pacheco JA, Elsawy MA, Reyes-Martínez JE, Enríquez-Rodríguez AI. Self-assembling peptides as an emerging platform for the treatment of metabolic syndrome. Int J Nanomedicine. 2020;15:10349-10370.
Ko S-C, Jeon Y-J. Marine peptides for preventing metabolic syndrome. Curr Protein Pept Sci. 2013;14:183-188.
Rehmani S, Dixon JE. Oral delivery of anti-diabetes therapeutics using cell penetrating and transcytosing peptide strategies. Peptides (NY). 2018;100:24-35.
Robinson SD, Safavi-Hemami H. Venom peptides as pharmacological tools and therapeutics for diabetes. Neuropharmacology. 2017;127:79-86.
Marya, Khan H, Nabavi SM, Habtemariam S. Anti-diabetic potential of peptides: future prospects as therapeutic agents. Life Sci. 2018;193:153-158.
Peterson SC, Barry AR. Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: a meta-analysis. Curr Diabetes Rev. 2018;14:273-279.
Grieco P, Gomez-Monterrey I. Natural and synthetic peptides in the cardiovascular diseases: an update on diagnostic and therapeutic potentials. Arch Biochem Biophys. 2019;662:15-32.
Recio C, Maione F, Iqbal AJ, Mascolo N, De Feo V. The potential therapeutic application of peptides and peptidomimetics in cardiovascular disease. Front Pharmacol. 2017;7:526.
Wimley WC, Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol. 2011;239:27-34.
Malmsten M. Antimicrobial peptides. Ups J Med Sci. 2014;119:199-204.
Torres MDT, Sothiselvam S, Lu TK, de la Fuente-Nunez C. Peptide design principles for antimicrobial applications. J Mol Biol. 2019;431:3547-3567.
Bahar AA, Ren D. Antimicrobial peptides. Pharmaceuticals. 2013;6:1543-1575.
Dadar M, Shahali Y, Chakraborty S, Prasad M, Tahoori F, Tiwari R, et al. Antiinflammatory peptides: current knowledge and promising prospects. Inflamm Res. 2019;68:125-145.
La Manna S, Di Natale C, Florio D, Marasco D. Peptides as therapeutic agents for inflammatory-related diseases. Int J Mol Sci. 2018;19:2714.
Liu W, Chen X, Li H, Zhang J, An J, Liu X. Anti-inflammatory function of plant-derived bioactive peptides: a review. Foods. 2022;11:2361.
Yadav A, Pandey D, Ashraf GM, Rachana. Peptide based therapy for neurological disorders. Curr Protein Pept Sci. 2021;22:656-665.
Tiwari SK, Chaturvedi RK. Peptide therapeutics in neurodegenerative disorders. Curr Med Chem. 2014;21:2610-2631.
Yazbeck R. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. Curr Opin Mol Ther. 2010;12:798-809.
Corsetti M, Tack J. Linaclotide: a new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. United European Gastroenterol J. 2013;1:7-20.
McKeage K. Pasireotide: a review of its use in Cushing's disease. Drugs. 2013;73:563-574.
Council of Europe. European pharmacopoeia (Ph. Eur.) 11th edition. Strasbourg, France: Council of Europe. 2022 https://www.edqm.eu/en/european-pharmacopoeia-ph.-eur.-11th-edition. Accessed 4 Aug 2023.
British Pharmacopoeia Commission. British Pharmacopoeia (BP) 2022. London, Great Britain: British Pharmacopoeia Commission. 2022 https://www.pharmacopoeia.com/Subscriptions/ProductDetails?productId=100002301x
Steinberg DA, Hurst MA, Fujii CA, Kung AH, Ho JF, Cheng FC, et al. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother. 1997;41:1738-1742.
Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309-318.
Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645-1658.
Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3:710-720.
Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415:389-395.
Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. Clin Microbiol Rev. 2006;19:491-511.
Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol. 2007;120:13-22.
Zhang L, Gallo RL. Antimicrobial peptides. Curr Biol. 2016;26:R14-R19.
Davies J. Where have all the antibiotics gone? Can J Infect Dis Med Microbiol. 2006;17:287-290.
Huan Y, Kong Q, Mou H, Yi H. Antimicrobial peptides: classification, design, application and research progress in multiple fields. Front Microbiol. 2020;11:582779.
Shafee TMA, Lay FT, Phan TK, Anderson MA, Hulett MD. Convergent evolution of defensin sequence, structure and function. Cell Mol Life Sci. 2017;74:663-682.
Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985;76:1427-1435.
Kościuczuk EM, Lisowski P, Jarczak J, Strzałkowska N, Jóźwik A, Horbańczuk J, et al. Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep. 2012;39:10957-10970.
Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti M. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biol Chem. 1996;271:28375-28381.
Risso A, Zanetti M, Gennaro R. Cytotoxicity and apoptosis mediated by two peptides of innate immunity. Cell Immunol. 1998;189:107-115.
van Dijk A, Veldhuizen EJA, van Asten AJAM, Haagsman HP. CMAP27, a novel chicken cathelicidin-like antimicrobial protein. Vet Immunol Immunopathol. 2005;106:321-327.
Senyürek I, Paulmann M, Sinnberg T, Kalbacher H, Deeg M, Gutsmann T, et al. Dermcidin-derived peptides show a different mode of action than the cathelicidin LL-37 against Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:2499-2509.
Schittek B. The multiple facets of dermcidin in cell survival and host defense. J Innate Immun. 2012;4:349-360.
Steffen H, Rieg S, Wiedemann I, Kalbacher H, Deeg M, Sahl H-G, et al. Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. Antimicrob Agents Chemother. 2006;50:2608-2620.
Krensky AM. Granulysin: a novel antimicrobial peptide of cytolytic T lymphocytes and natural killer cells. Biochem Pharmacol. 2000;59:317-320.
Chatterjee S, Chatterjee S, Lad SJ, Phansalkar MS, Rupp RH, Ganguli BN, et al. Mersacidin, a new antibiotic from Bacillus: fermentation, isolation, purification and chemical characterization. J Antibiot (Tokyo). 1992;45:832-838.
ClinicalTrials.gov. A study to evaluate safety, tolerability and efficacy of LytixarTM (LTX-109) on uncomplicated, gram-positive, skin infection. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01223222. Accessed 19 Apr 2023.
Zhang B-Y, Li S-M, Gao Z-H, Shen J-H. Protective effects of snake venom antimicrobial peptide OH-CATH on E. coli induced rabbit urinary tract infection models. Kunming: Kunming Institute of Zoology, Chinese Academy of Sciences; 2013. https://tspace.library.utoronto.ca/handle/1807/64827
Suzuki Y, Yazawa I. Pathological accumulation of atrophin-1 in dentatorubral-pallidoluysian atrophy. Int J Clin Exp Pathol. 2011;4:378-384.
Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet. 1996;14:277-284.
Orr HT, Chung MY, Banfi S, Kwiatkowski TJ, Servadio A, Beaudet AL, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4:221-226.
Popiel HA, Burke JR, Strittmatter WJ, Oishi S, Fujii N, Takeuchi T, et al. The aggregation inhibitor peptide QBP1 as a therapeutic molecule for the polyglutamine neurodegenerative diseases. J Amino Acids. 2011;2011:265084.
Kamerkar SC, Kraus F, Sharpe AJ, Pucadyil TJ, Ryan MT. Dynamin-related protein 1 has membrane constricting and severing abilities sufficient for mitochondrial and peroxisomal fission. Nat Commun. 2018;9:5239.
Filichia E, Hoffer B, Qi X, Luo Y. Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson's disease model induced by MPTP. Sci Rep. 2016;6:32656.
Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, Gutierrez A, Gozes I, Vitorica J, et al. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci. 2010;41:114-120.
Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, et al. Davunetide for progressive supranuclear palsy: a multicenter, randomized, double-blind, placebo controlled trial. Lancet Neurol. 2014;13:676-685.
Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45:25-39.
Tunçel N, Şener E, Cerit C, Karasu U, Gürer F, Şahintürk V, et al. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy. Peptides (NY). 2005;26:827-836.
Korkmaz OT, Tunçel N, Tunçel M, Öncü EM, Şahintürk V, Çelik M. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J Mol Neurosci. 2010;41:278-287.
Fahrenkrug J, Popovic N, Georg B, Brundin P, Hannibal J. Decreased VIP and VPAC2 receptor expression in the biological clock of the R6/2 Huntington's disease mouse. J Mol Neurosci. 2007;31:139-148.
Franco-Iborra S, Vila M, Perier C. The Parkinson disease mitochondrial hypothesis: where are we at? Neuroscientist. 2016;22:266-277.
Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. J Neurochem. 2016;139:216-231.
Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? J Neurosci Res. 2005;79:231-239.
Martins NM, Ferreira DAS, Carvalho Rodrigues MA, Cintra ACO, Santos NAG, Sampaio SV, et al. Low-molecular-mass peptides from the venom of the Amazonian viper Bothrops atrox protect against brain mitochondrial swelling in rat: potential for neuroprotection. Toxicon. 2010;56:86-92.
Dong Y, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J. 2011;25:2911-2920.
Chiangjong W, Chutipongtanate S, Hongeng S. Anticancer peptide: physicochemical property, functional aspect and trend in clinical application (Review). Int J Oncol. 2020;57:678-696.
Serafino A, Pierimarchi P. Atrial natriuretic peptide: a magic bullet for cancer therapy targeting Wnt signaling and cellular pH regulators. Curr Med Chem. 2014;21:2401-2409.
Nguyen JP, Frost CD, Lane ML, Skelton WP, Skelton M, Vesely DL. Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor. Eur J Clin Invest. 2012;42:1061-1067.
Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4:97-105.
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273-286.
Vesely DL. Atrial natriuretic peptides: anticancer agents. J Investig Med. 2005;53:360-365.
Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, et al. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research. Mol Cell Biochem. 2011;356:45-50.
Garay H, Espinosa LA, Perera Y, Sánchez A, Diago D, Perea SE, et al. Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: a clinical-grade anticancer synthetic peptide. J Peptide Sci. 2018;24:e3081.
Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, et al. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer. 2009;9:146.
Sarduy MR, García I, Coca MA, Perera A, Torres LA, Valenzuela CM, et al. Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer. Br J Cancer. 2015;112:1636-1643.
Haney EF, Straus SK, Hancock REW. Reassessing the host defense peptide landscape. Front Chem. 2019;7:43.
Drayton M, Deisinger JP, Ludwig KC, Raheem N, Müller A, Schneider T, et al. Host defense peptides: dual antimicrobial and immunomodulatory action. Int J Mol Sci. 2021;22:11172.
Eike L-M, Yang N, R Ø, Sveinbjørnsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget. 2015;6:34910-34923.
Sveinbjørnsson B, Camilio KA, Haug BE, Rekdal Ø LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment. Future Med Chem. 2017;9:1339-1344.
González-Montoya M, Hernández-Ledesma B, Silván JM, Mora-Escobedo R, Martínez-Villaluenga C. Peptides derived from in vitro gastrointestinal digestion of germinated soybean proteins inhibit human colon cancer cells proliferation and inflammation. Food Chem. 2018;242:75-82.
Hirschstein Z, Novakovic ZM, Grasso P. MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, normalizes glucose tolerance and episodic memory in a mouse model of type 2 diabetes mellitus and Alzheimer's disease-like cognitive impairment. Int J Pept Res Ther. 2020;26:1981-1990.
Craig SL, Irwin N, Gault VA. Xenin and related peptides: potential therapeutic role in diabetes and related metabolic disorders. Clin Med Insights Endocrinol Diabetes. 2021;14:11795514211043868.
Martin CM, Parthsarathy V, Hasib A, Ng MT, McClean S, Flatt PR, et al. Biological activity and antidiabetic potential of C-terminal octapeptide fragments of the gut-derived hormone xenin. PLoS One. 2016;11:e0152818.
Irwin N, Green BD, Parker JC, Gault VA, O'Harte FPM, Flatt PR. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16). Regul Pept. 2006;135:45-53.
Patterson S, de Kort M, Irwin N, Moffett RC, Dokter WHA, Bos ES, et al. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide. Diabetes Obes Metab. 2015;17:760-770.
Irwin N, Patterson S, de Kort M, Moffett RC, Wisse JAJ, Dokter WHA, et al. Synthesis and evaluation of a series of long-acting glucagon-like peptide-1 (GLP-1) pentasaccharide conjugates for the treatment of type 2 diabetes. ChemMedChem. 2015;10:1424-1434.
Attoub S, Mechkarska M, Sonnevend A, Radosavljevic G, Jovanovic I, Lukic ML, et al. Esculentin-2CHa: a host-defense peptide with differential cytotoxicity against bacteria, erythrocytes and tumor cells. Peptides (NY). 2013;39:95-102.
Ojo OO, Srinivasan DK, Owolabi BO, Vasu S, Conlon JM, Flatt PR, et al. Esculentin-2CHa-related peptides modulate islet cell function and improve glucose tolerance in mice with diet-induced obesity and insulin resistance. PLoS One. 2015;10:e0141549.
Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, et al. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem Biophys Res Commun. 2004;319:746-752.
Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: prospects for use in the treatment of COVID-19. Molecules. 2020;25:4389.
Nelde A, Rammensee H-G, Walz JS. The peptide vaccine of the future. Mol Cell Proteomics. 2021;20:100022.
Carter JM. Conjugation of peptides to carrier proteins via glutaraldehyde. In: Walker JM, editor. The protein protocols handbook. Totowa, NJ: Humana Press; 1996. p. 679-687.
Ravasco JMJM, Faustino H, Trindade A, Gois PMP. Bioconjugation with maleimides: a useful tool for chemical biology. Chem Eur J. 2019;25:43-59.
Lin SY-H, Cheng C-W, Su EC-Y. Prediction of B-cell epitopes using evolutionary information and propensity scales. BMC Bioinformatics. 2013;14:S10.
Bijker MS, Melief CJ, Offringa R, van der Burg SH. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines. 2007;6:591-603.
Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: current progress and future challenges. Chem Rev. 2020;120:3210-3229.
Ghasparian A, Moehle K, Linden A, Robinson JA. Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. Chem Commun (Camb). 2006;2006(2):174-176.
Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine. 2003;21:921-924.
Okitsu SL, Kienzl U, Moehle K, Silvie O, Peduzzi E, Mueller MS, et al. Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem Biol. 2007;14:577-587.
Hodder AN, Crewther PE, Matthew ML, Reid GE, Moritz RL, Simpson RJ, et al. The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem. 1996;271:29446-29452.
Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, Crabb BS, et al. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol. 2000;38:706-718.
Mueller MS, Renard A, Boato F, Vogel D, Naegeli M, Zurbriggen R, et al. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect Immun. 2003;71:4749-4758.
Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS One. 2007;2:e1018.
Cech PG, Aebi T, Abdallah MS, Mpina M, Machunda EB, Westerfeld N, et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS One. 2011;6:e22273.
Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine. 2006;24:4343-4353.
Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology. 2008;134:1385-1395.
Klade CS, Schuller E, Boehm T, von Gabain A, Manns MP. Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine. 2012;30:2943-2950.
Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, et al. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine. 2014;32:5816-5823.
Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, et al. Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J Clin Immunol. 2012;32:595-603.
van Doorn E, Liu H, Ben-Yedidia T, Hassin S, Visontai I, Norley S, et al. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine. Medicine. 2017;96:e6339.
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2021;22:74-85.
Rammensee H-G, Wiesmüller K-H, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, et al. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. J Immunother Cancer. 2019;7:307.
Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature. 2022;601:617-622.
Akapirat S, Karnasuta C, Vasan S, Rerks-Ngarm S, Pitisuttithum P, Madnote S, et al. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS One. 2018;13:e0196397.
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, et al. The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012;28:1444-1457.
Vandenberghe R, Riviere M-E, Caputo A, Sovago J, Maguire RP, Farlow M, et al. Active Aβ immunotherapy CAD106 in Alzheimer's disease: a phase 2b study. Alzheimers Dement: Transl Res Clin Intervent. 2017;3:10-22.
Farlow MR, Andreasen N, Riviere M-E, Vostiar I, Vitaliti A, Sovago J, et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther. 2015;7:23.
Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11:597-604.
Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang T-Y, et al. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine. 2007;25:3041-3052.
Wang CY, Wang P-N, Chiu M-J, Finstad CL, Lin F, Lynn S, et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease. Alzheimers Dement (N Y). 2017;3:262-272.
Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci. 2013;33:4923-4934.
Lacosta A-M, Pascual-Lucas M, Pesini P, Casabona D, Pérez-Grijalba V, Marcos-Campos I, et al. Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res Ther. 2018;10:12.
Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, López-Deber MP, Reis P, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8:e72301.
Hickman DT, López-Deber MP, Ndao DM, Silva AB, Nand D, Pihlgren M, et al. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem. 2011;286:13966-13976.
Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res Ther. 2014;6:45.
Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014;6:44.
Novak P, Schmidt R, Kontsekova E, Kovacech B, Smolek T, Katina S, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Res Ther. 2018;10:108.
Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nat Aging. 2021;1:521-534.
Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: current trends in clinical application. Cell Prolif. 2021;54:e13025. https://doi.org/10.1111/cpr.13025
O'Konek JJ, Ambrosino E, Bloom AC, Pasquet L, Massilamany C, Xia Z, et al. Differential regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. Oncoimmunology. 2018;7:e1439305.
Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119-2127.
Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25:1735-1742.
Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016;7:66192-66201.
Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015;17:854-861.
Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, et al. Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. Clin Cancer Res. 2020;26:1586-1594.
Elsamadicy AA, Chongsathidkiet P, Desai R, Woroniecka K, Farber SH, Fecci PE, et al. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opin Biol Ther. 2017;17:507-513.
Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2:224-234.
Kašička V. Recent developments in capillary and microchip electroseparations of peptides (2017-mid 2019). Electrophoresis. 2020;41:10-35.
Kašička V. Recent developments in capillary and microchip electroseparations of peptides (2019-mid 2021). Electrophoresis. 2022;43:82-108.
Denoroy L, Parrot S. Analysis of amino acids and related compounds by capillary electrophoresis. Sep Purif Rev. 2017;46:108-151.
Ferré S, González-Ruiz V, Guillarme D, Rudaz S. Analytical strategies for the determination of amino acids: past, present and future trends. J Chromatogr B. 2019;1132:121819.
Piestansky J, Olesova D, Matuskova M, Cizmarova I, Chalova P, Galba J, et al. Amino acids in inflammatory bowel diseases: modern diagnostic tools and methodologies. In: Makowski GS, editor. Advances in clinical chemistry. Amsterdam: Elsevier; 2022. p. 139-213.
Ta HY, Collin F, Perquis L, Poinsot V, Ong-Meang V, Couderc F. Twenty years of amino acid determination using capillary electrophoresis: a review. Anal Chim Acta. 2021;1174:338233.
Lam PMW, Marczylo TH, El-Talatini M, Finney M, Nallendran V, Taylor AH, et al. Ultra performance liquid chromatography tandem mass spectrometry method for the measurement of anandamide in human plasma. Anal Biochem. 2008;380:195-201.
Kang L, Weng N, Jian W. LC-MS bioanalysis of intact proteins and peptides. Biomed Chromatogr. 2020;34:e4633.
Yeung D, Klaassen N, Mizero B, Spicer V, Krokhin OV. Peptide retention time prediction in hydrophilic interaction liquid chromatography: zwitter-ionic sulfoalkylbetaine and phosphorylcholine stationary phases. J Chromatogr A. 2020;1619:460909.
Týčová A, Ledvina V, Klepárník K. Recent advances in CE-MS coupling: instrumentation, methodology, and applications. Electrophoresis. 2017;38:115-134.
Breadmore MC, Wuethrich A, Li F, Phung SC, Kalsoom U, Cabot JM, et al. Recent advances in enhancing the sensitivity of electrophoresis and electrochromatography in capillaries and microchips (2014-2016). Electrophoresis. 2017;38:33-59.
Breadmore MC, Grochocki W, Kalsoom U, Alves MN, Phung SC, Rokh MT, et al. Recent advances in enhancing the sensitivity of electrophoresis and electrochromatography in capillaries and microchips (2016-2018). Electrophoresis. 2019;40:17-39.
Sonker M, Sahore V, Woolley AT. Recent advances in microfluidic sample preparation and separation techniques for molecular biomarker analysis: a critical review. Anal Chim Acta. 2017;986:1-11.
Waterval JCM, Bestebreurtje P, Lingeman H, Versluis C, Heck AJR, Bult A, et al. Robust and cost-effective capillary electrophoresis-mass spectrometry interfaces suitable for combination with on-line analyte preconcentration. Electrophoresis. 2001;22:2701-2708.
Waterval JCM, Hommels G, Teeuwsen J, Bult A, Lingeman H, Underberg WJM. Quantitative analysis of pharmaceutically active peptides using on-capillary analyte preconcentration transient isotachophoresis. Electrophoresis. 2000;21:2851-2858.
Kitagawa S, Noji A, Matsushita N, Nakagawa H, Asai T, Ohitani H. Large-volume sample on-line concentration of angiotensins in non-aqueous capillary electrophoresis. Electrophoresis. 2011;32:1480-1485.
Otin J, Tran NT, Benoit A, Buisson C, Taverna M. Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis. Electrophoresis. 2023;44:807-817.
Chen Y, Xu L, Lin J, Chen G. Assay of bradykinin-related peptides in human body fluids using capillary electrophoresis with laser-induced fluorescence detection. Electrophoresis. 2008;29:1302-1307.
Ramautar R, Ratnayake CK, Somsen GW, de Jong GJ. Capillary electrophoresis-mass spectrometry using an in-line sol-gel concentrator for the determination of methionine enkephalin in cerebrospinal fluid. Talanta. 2009;78:638-642.
Hernández E, Benavente F, Sanz-Nebot V, Barbosa J. Analysis of opioid peptides by on-line SPE-CE-ESI-MS. Electrophoresis. 2007;28:3957-3965.
Tempels FWA, Underberg WJM, Somsen GW, de Jong GJ. On-line coupling of SPE and CE-MS for peptide analysis. Electrophoresis. 2007;28:1319-1326.
Mancera-Arteu M, Benavente F, Sanz-Nebot V, Giménez E. Sensitive analysis of recombinant human erythropoietin glycopeptides by on-line phenylboronic acid solid-phase extraction capillary electrophoresis mass spectrometry. J Proteome Res. 2023;22:826-836.
Mancera-Arteu M, Lleshi N, Sanz-Nebot V, Giménez E, Benavente F. Analysis of glycopeptide biomarkers by on-line TiO2 solid-phase extraction capillary electrophoresis-mass spectrometry. Talanta. 2020;209:120563.
Nyssen L, Fillet M, Cavalier E, Servais A. Highly sensitive and selective separation of intact parathyroid hormone and variants by sheathless CE-ESI-MS/MS. Electrophoresis. 2019;40:1550-1557.
Štěpánová S, Kašička V. Determination of impurities and counterions of pharmaceuticals by capillary electromigration methods. J Sep Sci. 2014;37:2039-2355.
El Deeb S, Wätzig H, Abd El-Hady D, Sänger-van de Griend C, Scriba GKE. Recent advances in capillary electrophoretic migration techniques for pharmaceutical analysis (2013-2015). Electrophoresis. 2016;37:1591-1608.
Tamizi E, Jouyban A. The potential of the capillary electrophoresis techniques for quality control of biopharmaceuticals-a review. Electrophoresis. 2015;36:831-858.
Van Schepdael A. Capillary electrophoresis as a simple and low-cost analytical tool for use in money-constrained situations. TrAC Trends Anal Chem. 2023;160:116992.
Salim MM, Ebeid WM, El-Enany N, Belal F, Walash M, Patonay G. Simultaneous determination of aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide in their triple mixture dosage form by capillary zone electrophoresis. J Sep Sci. 2014;37:1206-1213.
Tůmová T, Monincová L, Nešuta O, Čeřovský V, Kašička V. Determination of effective charges and ionic mobilities of polycationic antimicrobial peptides by capillary isotachophoresis and capillary zone electrophoresis. Electrophoresis. 2017;38:2018-2024.
Šolínová V, Kašička V. Determination of acidity constants and ionic mobilities of polyprotic peptide hormones by CZE. Electrophoresis. 2013;34:2655-2665.
Šolínová V, Kašička V, Sázelová P, Barth T, Mikšík I. Separation and investigation of structure-mobility relationship of gonadotropin-releasing hormones by capillary zone electrophoresis in conventional and isoelectric acidic background electrolytes. J Chromatogr A. 2007;1155:146-153.
Wätzig H, Degenhardt M. Characterisation of buserelin acetate by capillary electrophoresis. J Chromatogr A. 1998;817:239-252.
Tamizi E, Kenndler E, Jouyban A. A stability indicating capillary electrophoresis method for analysis of buserelin. Iran J Pharm Res. 2014;13:797-807.
Lodén H, Amini A. Quantification of buserelin in a pharmaceutical product by multiple-injection CZE. Electrophoresis. 2007;28:1548-1556.
Sázelová P, Kašička V, Šolínová V, Koval D. Determination of purity degree and counter-ion content in lecirelin by capillary zone electrophoresis and capillary isotachophoresis. J Chromatogr B. 2006;841:145-151.
Amini A, Olofsson I-M. Analysis of calcitonin and its analogues by capillary zone electrophoresis and matrix-assisted laser-desorption ionization time-of-flight mass spectrometry. J Sep Sci. 2004;27:675-685.
Benković G, Škrlin A, Madić T, Debeljak Ž, Medić-Šarić M. Purity assessment of recombinant human granulocyte colony-stimulating factor in finished drug product by capillary zone electrophoresis. Electrophoresis. 2014;35:2608-2614.
Zhou G-H, Luo G-A, Sun G-Q, Cao Y-C, Zhang X-D, Zhang X. Characterization of recombinant human granulocyte colony stimulating factor (rHuG-CSF) by capillary zone electrophoresis, capillary isoelectric focusing electrophoresis and electrospray ionization mass spectrometry. J Pharm Biomed Anal. 2004;35:425-432.
Tamizi E, Jouyban A. A simple stability indicating CZE method for the analysis of octreotide acetate. Chromatographia. 2014;77:1347-1357.
Šolínová V, Kašička V, Barth T, Hauzerová L, Fanali S. Analysis and separation of enkephalin and dalargin analogues and fragments by capillary zone electrophoresis. J Chromatogr A. 2005;1081:9-18.
Creamer JS, Krauss ST, Lunte SM. Capillary electrophoresis separation of the desamino degradation products of oxytocin. Electrophoresis. 2014;35:563-569.
Šolı́nová V, Kašička V, Koval D, Barth T, Ciencialová A, Žáková L. Analysis of synthetic derivatives of peptide hormones by capillary zone electrophoresis and micellar electrokinetic chromatography with ultraviolet-absorption and laser-induced fluorescence detection. J Chromatogr B. 2004;808:75-82.
Amini A. Analysis of somatropin by double-injection capillary-zone electrophoresis in polybrene/chondroitin sulfate a double-coated capillaries. Methods Mol Biol. 2016;1466:93-105.
Wilhelmsen TW, Skibeli V, Arntzen FC. Stability study of somatropin by capillary zone electrophoresis. Procedia Chem. 2010;2:34-45.
Catai JR, Sastre Toraño J, Jongen PMJM, de Jong GJ, Somsen GW. Analysis of recombinant human growth hormone by capillary electrophoresis with bilayer-coated capillaries using UV and MS detection. J Chromatogr B. 2007;852:160-166.
Taichrib A, Scriba GKE, Neusüß C. Identification and characterization of impurities of tetracosactide by capillary electrophoresis and liquid chromatography coupled to time-of-flight mass spectrometry. Anal Bioanal Chem. 2011;401:1365-1375.
Musenga A, Mandrioli R, Zecchi V, Luppi B, Fanali S, Raggi MA. Capillary electrophoretic analysis of the antibiotic vancomycin in innovative microparticles and in commercial formulations. J Pharm Biomed Anal. 2006;42:32-38.
Ridge S, Hettiarachchi K. Peptide purity and counter ion determination of bradykinin by high-performance liquid chromatography and capillary electrophoresis. J Chromatogr A. 1998;817:215-222.
Vida RG, Fittler A, Mikulka I, Ábrahám E, Sándor V, Kilár F, et al. Availability and quality of illegitimate somatropin products obtained from the Internet. Int J Clin Pharm. 2017;39:78-87.
Sanz-Nebot V, Benavente F, Balaguer E, Barbosa J. Capillary electrophoresis coupled to time of flight-mass spectrometry of therapeutic peptide hormones. Electrophoresis. 2003;24:883-891.
Haselberg R, Brinks V, Hawe A, de Jong GJ, Somsen GW. Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals. Anal Bioanal Chem. 2011;400:295-303.
Gross PC, Burkart SC, Müller R. Analytics of the therapeutic peptide aviptadil by sheathless CE-MS and comparison with nanoRP-HPLC-MS. J Pharm Biomed Anal. 2014;88:477-482.
Hoitink MA. Capillary zone electrophoresis-mass spectrometry as a tool in the stability research of the luteinising hormone-releasing hormone analogue goserelin. J Chromatogr A. 1997;776:9.
Tamizi E, Yang Y, Jouyban A, Kelso GF, Boysen RI, Hearn MTW. A capillary electrophoretic-mass spectrometric method for the assessment of octreotide stability under stress conditions. J Chromatogr A. 2016;1429:354-363.
Sanz-Nebot V, Balaguer E, Benavente F, Barbosa J. Comparison of sheathless and sheath-flow electrospray interfaces for the capillary electrophoresis-electrospray ionization-mass spectrometry analysis of peptides. Electrophoresis. 2005;26:1457-1465.
Piešťanský J, Čižmárová I, Štefánik O, Matušková M, Horniaková A, Majerová P, et al. Capillary electrophoresis-mass spectrometry with multisegment injection and in-capillary preconcentration for high-throughput and sensitive determination of therapeutic decapeptide triptorelin in pharmaceutical and biological matrices. Biomedicines. 2021;9:1488.
Le TB, Hauser PC, Pham TNM, Kieu TLP, Le TPQ, Hoang QA, et al. Low-cost and versatile analytical tool with purpose-made capillary electrophoresis coupled to contactless conductivity detection: application to antibiotics quality control in Vietnam. Electrophoresis. 2020;41:1980-1990.
Sangoi MS, Wrasse-Sangoi M, Hurtado FK, Rolim CMB. Stress degradation studies on aliskiren and the development of a sensitive stability-indicating MEKC method. Acta Chromatogr. 2013;25:711-724.
Kang J, De Reymaeker G, Van Schepdael A, Roets E, Hoogmartens J. Analysis of bacitracin by micellar electrokinetic capillary chromatography with mixed micelle in acidic solution. Electrophoresis. 2001;22:1356-1362.
Injac R, Mlinaric A, Djorjevic-Milic V, Karljikovic-Rajic K, Strukelj B. Optimal conditions for determination of zinc bacitracin, polymyxin B, oxytetracycline and sulfacetamide in animal feed by micellar electrokinetic capillary chromatography. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008;25:424-431.
Gotti R, Furlanetto S, Santagati NA. Analysis of cyclosporin A and main degradation impurities by cyclodextrin-modified micellar electrokinetic chromatography. Anal Lett. 2012;45:665-676.
Kang J, Vankeirsbilck T, Van Schepdael A, Orwa J, Roets E, Hoogmartens J. Analysis of colistin sulfate by capillary zone electrophoresis with cyclodextrins as additive. Electrophoresis. 2000;21:3199-3204.
Lamalle C, Servais A-C, Demelenne A, Crommen J, Fillet M. Analysis of protamine peptides in insulin pharmaceutical formulations by capillary electrophoresis. J Sep Sci. 2016;39:1189-1194.
Guek M, Gaspari M, Walhagen K, Vreeken RJ, Verheij ER, Van Der Greef J. Capillary electrochromatography/nanoelectrospray mass spectrometry for attomole characterization of peptides. Rapid Commun Mass Spectrom. 2000;14:1448-1454.
Shaltout EL, Al-Ghobashy MA, Fathalla FA, Salem MY. Chromatographic and electrophoretic assessment of Filgrastim biosimilars in pharmaceutical formulations. J Pharm Biomed Anal. 2014;97:72-80.
Tu M, Liu H, Zhang R, Chen H, Mao F, Cheng S, et al. Analysis and evaluation of the inhibitory mechanism of a novel angiotensin-I-converting enzyme inhibitory peptide derived from casein hydrolysate. J Agric Food Chem. 2018;66:4139-4144.
Jaworska M, Kłaczkow G, Wilk M, Anuszewska E. Analysis of biologically active peptides using two-dimensional HPLC-CE. Acta Pol Pharm. 2012;69:799-808.
Sastre Toraño J, Ramautar R, de Jong G. Advances in capillary electrophoresis for the life sciences. J Chromatogr B. 2019;1118-1119:116-136.
Kristoff CJ, Bwanali L, Veltri LM, Gautam GP, Rutto PK, Newton EO, et al. Challenging bioanalyses with capillary electrophoresis. Anal Chem. 2020;92:49-66.
Kubáň P, Dvořák M, Kubáň P. Capillary electrophoresis of small ions and molecules in less conventional human body fluid samples: a review. Anal Chim Acta. 2019;1075:1-26.
Šolínová V, Sázelová P, Mášová A, Jiráček J, Kašička V. Application of capillary and free-flow zone electrophoresis for analysis and purification of antimicrobial β-alanyl-tyrosine from hemolymph of fleshfly Neobellieria bullata. Molecules. 2021;26:5636.
Huang Y, Duan J, Jiang X, Chen H, Chen G. Separation and determination of enkephalin-related peptides using capillary electrophoresis. J Sep Sci. 2005;28:2534-2539.
Waterval JCM, Hommels G, Bestebreurtje P, Versluis C, Heck AJR, Bult A, et al. Capillary electrophoretic bioanalysis of therapeutically active peptides with UV and mass spectrometric detection after on-capillary preconcentration. Electrophoresis. 2001;22:2709-2716.
Staňová A, Marák J, Maier V, Ranc V, Znaleziona J, Ševčík J, et al. Analysis of buserelin in urine by online combination of capillary zone electrophoresis with electrospray mass spectrometry. Electrophoresis. 2010;31:1234-1240.
Staňová A, Marák J, Rezeli M, Páger C, Kilár F, Kaniansky D. Analysis of therapeutic peptides in human urine by combination of capillary zone electrophoresis-electrospray mass spectrometry with preparative capillary isotachophoresis sample pretreatment. J Chromatogr A. 2011;1218:8701-8707.
Kitahashi T, Furuta I. Determination of vancomycin in human serum by micellar electrokinetic capillary chromatography with direct sample injection. Clin Chim Acta. 2001;312:221-225.
Riekkola M-L, Jussila M, Porras SP, Valkó IE. Non-aqueous capillary electrophoresis. J Chromatogr A. 2000;892:155-170.
Kenndler E. A critical overview of non-aqueous capillary electrophoresis. Part I: Mobility and separation selectivity. J Chromatogr A. 2014;1335:16-30.
Li Y, Wojcik R, Dovichi NJ, Champion MM. Quantitative multiple reaction monitoring of peptide abundance introduced via a capillary zone electrophoresis-electrospray interface. Anal Chem. 2012;84:6116-6121.
Terabe S, Otsuka K, Ichikawa K, Tsuchiya A, Ando T. Electrokinetic separations with micellar solutions and open-tubular capillaries. Anal Chem. 1984;56:111-113.
Yang L, Lee CS. Micellar electrokinetic chromatography-mass spectrometry. J Chromatogr A. 1997;780:207-218.
Scriba GKE. Nonaqueous capillary electrophoresis-mass spectrometry. J Chromatogr A. 2007;1159:28-41.
Kenndler E. A critical overview of non-aqueous capillary electrophoresis. Part II: Separation efficiency and analysis time. J Chromatogr A. 2014;1335:31-41.
Cheng J, Chen DDY. Nonaqueous capillary electrophoresis mass spectrometry method for determining highly hydrophobic peptides. Electrophoresis. 2018;39:1216-1221.
Psurek A, Neusüß C, Pelzing M, Scriba GKE. Analysis of the lipophilic peptaibol alamethicin by nonaqueous capillary electrophoresis-electrospray ionization-mass spectrometry. Electrophoresis. 2005;26:4368-4378.
Psurek A, Matysik F-M, Scriba GKE. Determination of enkephalin peptides by nonaqueous capillary electrophoresis with electrochemical detection. Electrophoresis. 2006;27:1199-1208.
Haeberle S, Zengerle R. Microfluidic platforms for lab-on-a-chip applications. Lab Chip. 2007;7:1094-1110.
Koutny LB, Schmalzing D, Taylor TA, Fuchs M. Microchip electrophoretic immunoassay for serum cortisol. Anal Chem. 1996;68:18-22.
Hassan S. Microchip electrophoresis. Encyclopedia. 2021;1:30-41.
Hradski J, Chorváthová MD, Bodor R, Sabo M, Matejčík Š, Masár M. Quantitative aspects of microchip isotachophoresis for high precision determination of main components in pharmaceuticals. Anal Bioanal Chem. 2016;408:8669-8679.
Raith K, Althoff E, Banse J, Neidhardt H, Neubert RHH. Two examples of rapid and simple drug analysis in pharmaceutical formulations using capillary electrophoresis: naphazoline, dexamethasone and benzalkonium in nose drops and nystatin in an oily suspension. Electrophoresis. 1998;19:2907-2911.
Kaniansky D, Marák J, Masár M, Iványi F, Madajová V, Šimuničová E, et al. Capillary zone electrophoresis in a hydrodynamically closed separation system with enhanced sample loadability. J Chromatogr A. 1997;772:103.
Kaniansky D, Marák J. On-line coupling of capillary isotachophoresis with capillary zone electrophoresis. J Chromatogr A. 1990;498:191-204.
Mikuš P, Koval M, Maráková K, Piešt'Anský J, Havránek E. Separation possibilities of three-dimensional capillary electrophoresis. Talanta. 2013;103:294-300.
Piešt'anský J, Maráková K, Mikus P. Two-dimensional capillary electrophoresis with on-line sample preparation and cyclodextrin separation environment for direct determination of serotonin in human urine. Molecules. 2017;22:1668.
Hirokawa T, Kiso Y. Preparative procedures in isotachophoresis. J Chromatogr A. 1994;658:343-354.